SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...

CPT copyright 2013 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. CMS has approved Second Sight ...

Second Sight Medical Products shares trade more than 400% higher after the company reported that the FDA granted approval for its Argus 2s Retinal Prosthesis System designed to deliver useful ...

The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

The electrode takes over the function of damaged retinal cells, sending signals to a special pair of glasses that allows Lopez to see shapes and contrasting images. Lopez is the first patient to ...

USC and Second Sight Medical Products Inc., the developer of retinal prostheses for treating blindness, are expanding the clinical trial of an advanced retinal prosthesis into Europe. The announcement ...

People who suffer from retinitis pigmentosa (RP) have retinas that deteriorate over time, leading to progressive loss of sight. But last week, a U.S. Food and Drug Administration (FDA) panel ...

It was February 14, 2013, when the call Robert Greenberg had been patiently awaiting finally came. On the line were two FDA officials calling with a Valentine’s Day gift, Greenberg, CEO of Second ...